Mediwound Ltd (NASDAQ:MDWD) – Analysts at SunTrust Banks issued their Q1 2019 earnings estimates for shares of Mediwound in a research note issued on Monday. SunTrust Banks analyst B. Nudell forecasts that the biopharmaceutical company will post earnings per share of ($0.18) for the quarter. SunTrust Banks also issued estimates for Mediwound’s Q2 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.18) EPS and Q4 2019 earnings at ($0.15) EPS.

How to Become a New Pot Stock Millionaire

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings data on Monday, March 19th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.08. Mediwound had a negative net margin of 887.38% and a negative return on equity of 234.12%. The firm had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.65 million.

Several other equities research analysts have also recently issued reports on MDWD. ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 25th. Oppenheimer set a $10.00 price target on shares of Mediwound and gave the stock a “buy” rating in a research note on Friday, December 8th. Zacks Investment Research cut shares of Mediwound from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Finally, Wells Fargo decreased their price target on shares of Mediwound from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $9.25.

MDWD stock traded down $0.15 during trading on Wednesday, hitting $5.35. 27,437 shares of the company’s stock traded hands, compared to its average volume of 41,034. Mediwound has a one year low of $3.56 and a one year high of $8.25. The firm has a market cap of $147.41, a PE ratio of -5.41 and a beta of 0.15.

Several hedge funds have recently made changes to their positions in MDWD. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Mediwound by 5,084.4% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 754,434 shares of the biopharmaceutical company’s stock worth $3,357,000 after acquiring an additional 739,882 shares during the period. Meitav Dash Investments Ltd. purchased a new position in shares of Mediwound during the 4th quarter worth about $2,184,000. Alyeska Investment Group L.P. purchased a new position in shares of Mediwound during the 3rd quarter worth about $2,140,000. Nationwide Fund Advisors purchased a new position in shares of Mediwound during the 3rd quarter worth about $1,538,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Mediwound by 84.6% during the 4th quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 46,366 shares during the period. Institutional investors and hedge funds own 32.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Mediwound Ltd Expected to Post Q1 2019 Earnings of ($0.18) Per Share (MDWD)” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/mediwound-ltd-expected-to-post-q1-2019-earnings-of-0-18-per-share-mdwd/1960936.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.